Day 1 - Tuesday, 16 May 2017
Meeting category
Date(s)
16 May 2017 - 19 May 2017
Location
Lilongwe,
Malawi
INTEREST 2017
Related Enduring Materials
Enduring Materials
- 08:00
08:00
Registration desk open, walk in coffee & tea
Session 1: Official Opening Session -
Chairs
Sam Phiri, DCM, MSc, PhD
University of North Carolina School of Medicine, Chapel Hill, United States
Elly Katabira, MD, FRCP
Makerere University College of Health Sciences, Kampala, Uganda
9:00
Welcome and introductions
09:10
Welcome to Malawi, Minister of Health
Honourable Peter Kumpalume
Malawi
09:30
Welcome to Lilongwe, Mayor of Lilongwe
Councillor Desmond Bikoko
Malawi
09:45
HIV in Malawi, Department of Health
Thoko Kalua
Malawi
10:05
Progress in HIV prevention and treatment scale-up in sub-Saharan Africa
Karim Akadiri
UNAIDS
10:25
Announcements
10:30
Refreshment break and poster viewing [and private press briefing]
Symposium I: Treatment sequencing for the future - [AbbVie] -
Chairs
Sylvia Ojoo, MD
Kenya
11:00
Opening Remarks Chair
11:10
ART rapid scale-up: The implications for patient care and retention
Francesca Conradie, MBChB (Wits), DTM&H
South Africa
11:35
Treatment sequencing: second- and third-line ART in the era of integrase inhibitors
Carina Cesar
Argentina
12:15
Q&A
12:25
Closing Remarks Chair
12:30
Lunch and early career investigator meet the expert
Session 2: Lessons from HIV drug accessibility and prices -
Chairs
Catherine Hankins, MD, PhD, FRCPC, CM
Netherlands/Canada
13:30
Universal access to all essential medicines – What can be done?
Andrew Hill, MD
United Kingdom
13:55
Q&A
Symposium II: Differentiated care: What’s all the hype about? - [IAS] -
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Chair
Linda-Gail Bekker, MBCHB, DTMH, DCH, FCP(SA), PhD
South Africa
14:00
What is differentiated care and what is the global guidance to support scale-up?
Lynne Wilkinson
South Africa
14:15
What does differentiated care look like in Malawi?
Stanley Ngoma
Malawi
14:30
How can government support scale-up of differentiated care? The Zimbabwe Experience
Clorata Gwanzura
Zimbabwe
14:45
How can people living with HIV create demand for differentiated care?
Gift Trapence
Malawi
14:55
Can differentiated care support the transition of adolescents with HIV from paediatric to adult care?
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
15:00
Refreshment break and poster viewing
Session 3: Oral abstract presentations -
Chair
Stephen Watiti
Uganda
15:30
Using human resource and infrastructure costing analysis to determine required investments for scaling up HIV and AIDS services for meeting 90-90-90 prescribed treatment targets
M. Malema
Malawi
15:45
The costs of community based HIV self-test (HIV-ST) kit distribution: results from three (3) district sites in Zimbabwe
C. Mangenah
Zimbabwe
16:00
HIV-positive adolescents most at risk of onwards HIV transmission: quantitative findings from a community-traced sample in South Africa
E. Toska
South Africa
16:15
Hepatitis B virus infection in HIV-seronegative and HIVseropositive MSM in West Africa: prevalence, associated factors, and acceptability of vaccination (CohMSM ANRS 12324 – Expertise France)
T.T.E. Dah
Burkina Faso
Debate: Resolved that non-communicable diseases in people living with HIV are the next priority for HIV programmes in sub-Saharan Africa (Oxford rules) -
Peter Kilmarx, MD, FACP, FIDSA
Mark Nelson, MA, MBBS, FRCP
Chair
Peter Kilmarx, MD, FACP, FIDSA
USA
16:30
Opening remarks and voting
John E. Fogarty International Center, National Institutes of Health, USA
16:35
Team affirming the motion
Chelsea and Westminster Hospital / Imperial College Medical School, United Kingdom
16:42
Team opposing the motion
16:49
Comments from the audience
17:13
Team affirming the motion
Clara Banya
Malawi
17:17
Team opposing the motion
Nomagcaleka Rangana
South Africa
17:21
Summation affirming the motion
17:23
Summation opposing the motion
17:25
Voting and Conclusion by the Chair
17:30
Opening day reception at the BICC
Day 2 -Wednesday, 17 May 2017
Early morning sessions
(pre-registration at the registration desk is required for session 1 and 2)
- The Joep Lange Career Guidance Session
- Grantspersonship
- Poster Discussion Sessions
Session 4: Pre-exposure prophylaxis: PrEP in real life and new PrEP technologies -
Chairs
Mauro Schechter, MD, PhD
Brasil
08:00
PrEP choices and the PrEP pipeline: injectables, implants, and trial design challenges
Mina Hosseinipour
USA/Malawi
08:25
Q&A
Session 5: HIV risk, prevention, and young African women in 2017 -
Chairs
Peter Kilmarx
USA
N. Kumarasamy
India
08:30
The perfect storm: phylogenetics, age disparity, the vaginal microbiome, and HIV risk in young women
Ayesha Kharsany
South Africa
08:55
Q&A
09:00
Options for young women: DREAMS, GEMS, Multipurpose prevention technologies, PrEP
Kawango Agot
Kenya
09:25
Q&A
Mini-oral abstract presentations I -
Chairs
Charles Boucher, MD
Netherlands
09:30
The drug will help protect my tomorrow” : Awareness, willingness, and preferences to use pre-exposure prophylaxis (PrEP) among female sex workers in Lilongwe, Malawi
T. Lungu
Malawi
09:36
Sexual network testing as a strategy to reach the first 90; so much promise despite the barriers
E.A. Oladele
Nigeria
09:42
HIV, blame and shame: Pathways of risk to internalized HIV stigma among South African HIV-positive adolescents
M. Pantelic
South Africa
09:48
Prevalence and factors associated with unknown HIV status among HIV positive female sex workers: Rwanda behavioral and biological surveillance survey (BBSS) 2015
S.S, Malamba
Rwanda
09:54
HIV Incidence patterns and sexual behaviour in the era of ART, Karonga Prevention Study 2007 - 2011
C.Kanjala
Malawi
10:00
Refreshment break and poster viewing
Symposium III: Hepatitis B and co-infection: is Africa doomed? - [Gilead] -
Chair
Ponsiano Ocama
Uganda
10:30
Opening remarks and introduction
10:35
Hepatitis B in Africa: Epidemiology, pathophysiology and challenges
Ponsiano Ocama
Uganda
10:55
Management of HBV and HIV/HBV co-infection
Karine Lacombe
France
11:35
HBV advocacy presentation
Danjuma Adda
Nigeria
11:50
Q&A
11:55
Closing Remarks Chair
Session 6: Prevention of mother-to-child transmission and Option B+ -
Chair
Chewe Luo
USA/Zambia
12:00
Option B+ and male partner involvement
Andreas Jahn
Malawi
12:25
Q&A
12:30
Conference group picture
12:45
Lunch and early career investigator meet the expert
Session 7: Underserved, marginalised, stigmatized, and criminalised key populations in Africa, including transgender persons -
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Chairs
Elly Katabira
Uganda
Zengani Chirwa
Malawi
13:30
Overview of epidemiology, legal status, and programmes for and by men who have sex with men, sex workers, people who inject drugs, and prisoners in Africa
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
13:55
Q&A
14:00
Transgender persons in sub-Saharan Africa
Keletso Makofane
South Africa
14:25
Q&A
Mini-oral abstract presentations II -
Chairs
Kenly Sikwese
Zambia
Pierre-Marie Girard
France
14:30
Disclosure of sexual practices to family and healthcare providers by Men who have sex with Men in Nigeria
S. Amusu
Nigeria
14:36
Transactional sex among men who have sex with men (MSM) in Rwanda: Behavioral and biological surveillance survey 2015
A. Mbayiha
Rwanda
14:42
HIV and AIDS stigma: What drives the gender HIV/AIDS accepting attitudes gap in Malawi?
M. Chilongo
Malawi
14:48
Evaluating different linkage to HIV treatment implementation models for key populations living with HIV in Cameroon
I. Mfochive Njindam
Cameroon
14:54
Burden of HIV and sexually transmitted co-infections among the most-at-risk populations in East Africa: A review of the echo study
J. Kosgei
Kenya
15:00
Early experiences in integrating cervical cancer screening and treatment into HIV services in Zomba Central Hospital, Malaw
C. Pfaff
Malawi
15:06
Meeting the contraceptive needs of HIV + individuals with a “one Stop Shop” model in Antiretroviral (ART) clinics in northern part of Zambia
T. Malebe
Zambia
15:12
The persistence of violence and discrimination against MSM in Senegal aggravates their vulnerability. The experience of the association ADAMA
K. Diaw
Senegal
15:18
Partnership duration and HIV serostatus disclosure among people living with hiv/aids in Lilongwe, Malawi
T. Mbichila
Malawi
15:24
Cross sectional trend analysis of characteristics and management of presumptive TB patients in integrated TB/HIV facilities in Malawi: 2014-2016
W. Ng'ambi
Malawi
15:30
Refreshment break and poster viewing
Session 7: Update on HIV vaccine strategies, cure, and acute infection -
Chairs
Guido Ferrari
USA
16:00
HIV vaccine strategies
Merlin Robb
USA
16:25
Q&A
Viral reservoirs and insights for HIV cure in adults and children
Thumbi N’dungu
Lagos University Teaching Hospital, Nigeria
16:55
Q&A
Session 8: Tuberculosis in 2017 -
Chair
Serge Eholié
Côte d’Ivoire
17:00
Tuberculosis update and diagnostic challenges
Robin Wood
South Africa
17:25
Q&A
Day 3 - Thursday, 18 May 2017
Early morning sessions
(pre-registration at the registration desk is required for session 1 and 2)
- The Joep Lange Career Guidance Session
- Grantspersonship
- Poster Discussion Sessions
Session 9: HIV testing in 2017 -
Chair
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP (SA), PhD. South Africa
South Africa
08:00
Progress towards the first 90 in sub-Saharan Africa: innovative approaches, including self-testing
Liz Corbett
UK/Malawi
08:25
Q&A
Session 10: HIV treatment among adults in Africa in 2017 -
Chair
Charles Boucher, MD
Netherlands
08:30
Update on clinical HIV management in adults
08:55
Q&A
Symposium IV: Turning failure into success: Current concepts of 2nd and 3rd line ART in paediatrics and adolescents – [Johnson & Johnson] -
Chair
Chewe Luo
USA
09:00
Welcome and Introduction Chair
09:10
Optimizing 2nd and 3rd line ART in paediatrics and adolescents
Victor Musiime
Uganda
09:25
Managing transition from paediatric to adolescent to adult HIV care
Allyson McKenny
Malawi
09:40
Q&A
09:55
Closing Remarks Chair
10:00
Refreshment break and poster viewing
Session 11: Palliative and end-of-life care in Africa -
Chairs
François Venter, MD
South Africa
10:30
Comfort throughout the disease trajectory
Jane Nakawesi
Uganda
10:55
Q&A
Symposium V: Advancing HIV care in resource-limited settings (RLS): New approaches in 1st line ART - [Johnson & Johnson] -
Chairs
Sam Phiri
Malawi
11:00
Welcome and Introductions Chair
11:10
Introducing new options for 1st line ART in RLS
Michelle Moorhouse
South Africa
11:25
Emerging swtich strategies in 1st line ART
Paula Munderi
Uganda
11:40
Q&A
11:55
Closing Remarks Chair
12:00
Lunch and early career investigator meet the expert
Oral abstract presentations II -
Chair
Richard Koup
USA
Sabine Hermans
Netherlands
13:00
One year outcomes following availability of community-based HIV self-testing: uptake, accuracy and linkage into care in a prospective study in Blantyre, Malawi
A. Choko
Malawi
13:15
Using community-based HIV testing campaigns by lay health workers to identify signs and symptoms of tuberculosis in the Botswana Combination Prevention Project
L.A. Mills
Rwanda
13:30
Increased risk of treatment failure after low-level viremia in a large cohort of South African HIV-positive patients treated according to WHO guidelines
L. Hermans
South Africa
13:45
Implementation of the HIV “test-and-treat” strategy in Malawi prisons: experience, challenges, and effectiveness
S. Mendelsohn
Belgium
Symposium VI: The journey of diagnostics: the impact of diagnostics in the fight against HIV - [Roche] -
Chair
Reuben Mwenda
Malawi
14:00
Opening Remarks Chair
14:10
Scaling up against the odds - HIV in Nigeria
Sulieman Akanmu
Nigeria
14:20
Lesotho’s HIV Viral load scale up plan and how decentralization contributes to meeting the 90-90-90 goal
Mamakhetha Phalatse
Lesotho
14:30
Dry blood spot/free virus elution HIV viral load – Patient results vs. patient reach
Dorcus Abuya
Kenya
14:40
How to ensure the best results for patients
Tsakani Baloy
South Africa
14:50
Q&A
14:55
Closing Remarks Chair
15:00
Refreshment break and poster viewing
Mini-oral abstract presentations II -
Chairs
Robin Wood
South Africa
Serge Eholié
Côte d'Ivoire
15:30
Usability characteristics of HIV self- tests in Kenya
L. Ochieng
Kenya
15:36
Burden of HIV pretreatment drug resistance in Cameroon
G. F. Tchouwa
Cameroon
15:42
Linkage to treatment and retention amongst adolescents and young adults in a large antiretroviral treatment program in Nigeria
H.Khamofu
Nigeria
15:48
Loss to follow up among newly diagnosed HIV positive pregnant women in the option B+ program in Malawi
M. John
Malawi
15:54
Six month retention among patients initiated under Treat All learning phase in Zimbabwe: implications for national scale up in high prevalence, resource limited settings
K. Webb
Zimbabwe
16:00
Evaluation of a community defaulter tracing program focused on mothers who accessed the PMTCT option B+ program in Malawi
H. Jere
Malawi
16:06
CrAg positivity rates reported from a national CD4-reflexed screening programme identify high-risk regions of co-existent HIV/Cryptococcal disease, requiring urgent programmatic focus into care
L. Coetzee
South Africa
16:12
Validation of a screening tool to improve HIV case finding in pediatric wards in Malawi
D. Chasweka
Malawi
16:18
Moderate to high antiretroviral therapy adherence is optimal for virologic suppression in HIV-positive pregnant and breastfeeding Cameroonian women initiating “Option B+”: A prospective cohort study
P. Atanga
Cameroon
16:24
Prevalence and factors associated with antenatal depression among women enrolled in Option B+ PMTCT in Malawi
B. Harrington
Malawi
Symposium VII: Women and adolescent girls: Reasons to accelerate access to innovative antiretrovirals - [ViiV] -
Chair
Piotr Budnik
South Africa
16:30
Welcome and Introductions Chair
16:35
Treatment challenges experienced in women and young girls
Jack Wirima
Malawi
16:55
Stigma, gender inequality and disclosure: impact on adherence
Annemiek de Ruiter
United Kingdom
17:20
Q&A
17:30
Finger food reception at the Golden Peacock Hotel
Day 4 - Friday, 19 May 2019
Early morning sessions
(pre-registration at the registration desk is required for session 1 and 2)
- The Joep Lange Career Guidance Session
- Grantspersonship
- Poster Discussion Sessions.
Mini-oral abstract presentations IV -
Chair
08:00
Inclusive education for HIV-positive learners in primary schools
O. Gwayi
Malaw
08:06
Rate of antiretroviral drug substitution before and after the introduction of tenofovir based regimen in Malawi
B. Chavula
Malawi
08:12
Comparison of HIV-1 viral titre measurements using Plasma and Dried Blood Spots on Cobas AmpliPrep/TaqMan viral load assay Version 2.0 in western Kenya
F. Ogumbo
Kenya
08:18
Short and long term virological failure and HIV drug resistance in Cameroon
A. Aghokeng Fobang
Cameroon
08:24
Early ART in the community: Experiences from support groups in Hhohho, Swaziland
S. Mnisi
Swaziland
Session 10: Treatment optimisation: advocate perspectives -
Chairs
Polly Clayden
United Kingdom
Kenly Sikwese
Zambia
08:30
Treatment optimisation: advocate perspectives
Luckyboy Edison Mkhondwane
South Africa
08:50
Q&A
Symposium VIII: Can Africa lead Europe and North America in going digital? Digital innovation and the science of delivery - [Joep Lange Institute] -
Chair
Catherine Hankins
Netherlands/ Canada
09:05
Reaching adolescents
Craig Carty
South Africa/USA
09:17
Importance of unique identifiers and platforms
Ian de Vega
South Africa
09:29
Lessons from implementation
Millicent Olulu
Kenya
09:41
Panel discussion and public debate: Is Africa able to take lead in digital innovation?
10:00
Refreshment break and poster viewing
Session 11: Evidence for action: population-based impact assessments in Malawi, Zambia, and Zimbabwe -
Chair
Gertrude Chipungu
Malawi
10:35
Focus on Malawi (1)
Rose Nyirenda / Thoko Kalua
Malaw
10:45
Focus on Zambia
Crispin Moyo / Danielle Barradas
Zambia
10:55
Focus on Malawi (2)
Danielle Payne
West Africa
11:05
Focus on Zimbabwe
Leala Ruangtragool
Zimbabwe
11:15
Panel discussion and Q&A
Session 12: Countries and cities look to the future -
Chair
Peter Kilmarx
USA
Overview
Welcome
The annual INTEREST Conference is the premier scientific conference for HIV in Africa and brings together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world. The conference will showcase cutting-edge knowledge in the diagnosis and treatment of HIV and the prevention of the HIV-1 infection. Additionally, it will continue to foster building a community of African physicians and scientists to facilitate the implementation of local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission.
We would like to thank all of the participants of the 11th INTEREST Conference for their invaluable contribution in making this meeting such a success. We would also like to dedicate our gratitude to our sponsors, ViiV/GSK, Johnson & Johnson, Gilead, AbbVie, Roche, Mylan, NIH/Fogarty, Joep Lange Institute, IAS, ANRS and BD, for their generous support that made this event possible.
INTEREST is co-organised by Amsterdam Institute for Global Health and Development (AIGHD) and Virology Education.
Official Conference Website
Click here to visit the official conference website
Language
Related Programs
